FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1968420912> ?p ?o ?g. }

• W1968420912 endingPage "526" @default.
• W1968420912 startingPage "522" @default.
• W1968420912 abstract "To evaluate the safety and efficacy of infliximab in patients with primary sclerosing cholangitis.In this double-blind, placebo-controlled study, 24 patients with primary sclerosing cholangitis were screened and randomly assigned in a 2:1 ratio to receive infliximab (5 mg/kg) or placebo at weeks 0, 2, 6, 12, 18, and 24; patients were followed through week 52. The primary efficacy end point was a decrease of at least 50% in the serum alkaline phosphatase level from baseline to week 18. A blinded histologic assessment of liver biopsy samples, obtained at weeks 0 and 26, was performed using a predefined scoring system, including scores for inflammation, fibrosis, and cholestasis.Patient enrollment was prematurely stopped when results of an interim analysis showed no significant treatment benefit. Of the 24 patients screened, 10 were enrolled (6 patients received infliximab). Mean alkaline phosphatase levels at weeks 0, 18, and 52 were 349, 330, and 389 U/L, respectively, for the infliximab group and 481, 438, and 391 U/L, respectively, for the placebo group. Liver biopsy samples were analyzed in 7 patients (4 infliximab); no apparent differences could be detected in any of the histologic parameters. In 3 of 4 infliximab-treated patients and 2 of 3 placebo-treated patients, the disease stage did not change after 6 months of treatment. No meaningful changes were detected in the symptom score. No serious drug-related adverse events were observed.Study findings failed to demonstrate efficacy of infliximab in this small group of patients with established primary sclerosing cholangitis." @default.
• W1968420912 created "2016-06-24" @default.
• W1968420912 creator A5001383768 @default.
• W1968420912 creator A5018877451 @default.
• W1968420912 creator A5025170768 @default.
• W1968420912 creator A5034348684 @default.
• W1968420912 creator A5042501752 @default.
• W1968420912 creator A5044708113 @default.
• W1968420912 creator A5047607025 @default.
• W1968420912 creator A5052219587 @default.
• W1968420912 date "2008-05-01" @default.
• W1968420912 modified "2023-10-16" @default.
• W1968420912 title "A Double-blind, Placebo-controlled, Randomized Study of Infliximab in Primary Sclerosing Cholangitis" @default.
• W1968420912 cites W1583295409 @default.
• W1968420912 cites W1623139656 @default.
• W1968420912 cites W1665267469 @default.
• W1968420912 cites W1782151952 @default.
• W1968420912 cites W1851143213 @default.
• W1968420912 cites W1910841180 @default.
• W1968420912 cites W1934569577 @default.
• W1968420912 cites W1972034430 @default.
• W1968420912 cites W1985158145 @default.
• W1968420912 cites W1994344135 @default.
• W1968420912 cites W1995166288 @default.
• W1968420912 cites W1996821458 @default.
• W1968420912 cites W2000980750 @default.
• W1968420912 cites W2004329421 @default.
• W1968420912 cites W2005901103 @default.
• W1968420912 cites W2016020580 @default.
• W1968420912 cites W2036092291 @default.
• W1968420912 cites W2037271656 @default.
• W1968420912 cites W2047063457 @default.
• W1968420912 cites W2056110767 @default.
• W1968420912 cites W2059308519 @default.
• W1968420912 cites W2079967949 @default.
• W1968420912 cites W2090694192 @default.
• W1968420912 cites W2094166732 @default.
• W1968420912 cites W2099482902 @default.
• W1968420912 cites W2117842974 @default.
• W1968420912 cites W2125763073 @default.
• W1968420912 cites W2167543058 @default.
• W1968420912 cites W2171297959 @default.
• W1968420912 cites W2224685282 @default.
• W1968420912 cites W4292806894 @default.
• W1968420912 doi "https://doi.org/10.1097/mcg.0b013e3181662426" @default.
• W1968420912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18344886" @default.
• W1968420912 hasPublicationYear "2008" @default.
• W1968420912 type Work @default.
• W1968420912 sameAs 1968420912 @default.
• W1968420912 citedByCount "106" @default.
• W1968420912 countsByYear W19684209122012 @default.
• W1968420912 countsByYear W19684209122013 @default.
• W1968420912 countsByYear W19684209122014 @default.
• W1968420912 countsByYear W19684209122015 @default.
• W1968420912 countsByYear W19684209122016 @default.
• W1968420912 countsByYear W19684209122017 @default.
• W1968420912 countsByYear W19684209122018 @default.
• W1968420912 countsByYear W19684209122019 @default.
• W1968420912 countsByYear W19684209122020 @default.
• W1968420912 countsByYear W19684209122021 @default.
• W1968420912 countsByYear W19684209122022 @default.
• W1968420912 countsByYear W19684209122023 @default.
• W1968420912 crossrefType "journal-article" @default.
• W1968420912 hasAuthorship W1968420912A5001383768 @default.
• W1968420912 hasAuthorship W1968420912A5018877451 @default.
• W1968420912 hasAuthorship W1968420912A5025170768 @default.
• W1968420912 hasAuthorship W1968420912A5034348684 @default.
• W1968420912 hasAuthorship W1968420912A5042501752 @default.
• W1968420912 hasAuthorship W1968420912A5044708113 @default.
• W1968420912 hasAuthorship W1968420912A5047607025 @default.
• W1968420912 hasAuthorship W1968420912A5052219587 @default.
• W1968420912 hasConcept C126322002 @default.
• W1968420912 hasConcept C141071460 @default.
• W1968420912 hasConcept C142724271 @default.
• W1968420912 hasConcept C168563851 @default.
• W1968420912 hasConcept C197934379 @default.
• W1968420912 hasConcept C203092338 @default.
• W1968420912 hasConcept C204787440 @default.
• W1968420912 hasConcept C27081682 @default.
• W1968420912 hasConcept C2775934546 @default.
• W1968420912 hasConcept C2777138892 @default.
• W1968420912 hasConcept C2777766500 @default.
• W1968420912 hasConcept C2779134260 @default.
• W1968420912 hasConcept C2780615123 @default.
• W1968420912 hasConcept C71924100 @default.
• W1968420912 hasConcept C90924648 @default.
• W1968420912 hasConceptScore W1968420912C126322002 @default.
• W1968420912 hasConceptScore W1968420912C141071460 @default.
• W1968420912 hasConceptScore W1968420912C142724271 @default.
• W1968420912 hasConceptScore W1968420912C168563851 @default.
• W1968420912 hasConceptScore W1968420912C197934379 @default.
• W1968420912 hasConceptScore W1968420912C203092338 @default.
• W1968420912 hasConceptScore W1968420912C204787440 @default.
• W1968420912 hasConceptScore W1968420912C27081682 @default.
• W1968420912 hasConceptScore W1968420912C2775934546 @default.
• W1968420912 hasConceptScore W1968420912C2777138892 @default.
• W1968420912 hasConceptScore W1968420912C2777766500 @default.
• W1968420912 hasConceptScore W1968420912C2779134260 @default.

• next